Autonomic Nervous System Drugs Practice Questions

Q: Botulinum toxin is used in -

Focal dystonia. ***Focal dystonia*** - **Botulinum toxin** is a potent neurotoxin that relaxes muscles by blocking the release of **acetylcholine** at the neuromuscular junction. - In **focal dystonia**, specific muscles contract involuntarily, causing abnormal postures or movements; botulinum toxin injections can temporarily paralyze these muscles, reducing symptoms. *Myasthenia gravis* - **Myasthenia gravis** is an **autoimmune disease** characterized by muscle weakness due to antibodies blocking **acetylcholine receptors** at the neuromuscular junction. - Injecting **botulinum toxin** would further weaken the already compromised muscles, exacerbating the condition, and is therefore contraindicated. *Cerebellar ataxia* - **Cerebellar ataxia** results from damage to the **cerebellum**, leading to problems with coordination, balance, and fine motor control. - **Botulinum toxin** acts on the neuromuscular junction and would not address the underlying neurological deficit in the cerebellum. *Hypotonia* - **Hypotonia** refers to decreased muscle tone, often caused by problems in the brain, spinal cord, nerves, or muscles. - Using **botulinum toxin**, which causes muscle paralysis, would worsen **hypotonia** by further reducing muscle tone and strength.

Q: The following drug antagonizes the visceral side effects of neostigmine used for reversal of vecuronium blockade:

Atropine. ***Atropine*** - **Atropine** is an **anticholinergic drug** that blocks muscarinic receptors, effectively counteracting the **parasympathomimetic side effects** of neostigmine. - When neostigmine is used to reverse neuromuscular blockade, it inhibits **acetylcholinesterase**, increasing acetylcholine levels. This increased acetylcholine stimulates both nicotinic receptors (for muscle contraction) and muscarinic receptors (causing side effects like **bradycardia**, **salivation**, **bronchospasm**, and **gastrointestinal hypermotility**). Atropine selectively blocks these unwanted muscarinic effects. *Pilocarpine* - **Pilocarpine** is a **direct muscarinic agonist**, meaning it would exacerbate, rather than antagonize, the visceral side effects of neostigmine. - It is primarily used to treat **xerostomia** and **glaucoma** by increasing acetylcholine's effects on muscarinic receptors. *Pyridostigmine* - **Pyridostigmine** is another **cholinesterase inhibitor**, similar to neostigmine, and also used for reversal of neuromuscular blockade or in treating **myasthenia gravis**. - It would increase acetylcholine levels and thus enhance, not antagonize, the muscarinic side effects if used with neostigmine in this context. *Nicotine* - **Nicotine** is an agonist primarily acting on **nicotinic acetylcholine receptors**. - While neostigmine increases acetylcholine at nicotinic receptors to reverse muscle blockade, nicotine's primary action is not on muscarinic receptors to counteract the visceral side effects.

Q: A 72 year old woman presents with complaints of persistent urinary urgency, and incontinence. Her past medical history is significant for type 2 diabetes, for which she is currently taking glyburide, 5 mg twice daily. Which of the following is the most appropriate treatment for this patient?

Oxybutynin. ***Oxybutynin*** - **Oxybutynin** is an **anticholinergic medication** that reduces bladder muscle spasms and treats symptoms of an **overactive bladder**, such as urgency and incontinence, which are characteristic of this patient's presentation. - It works by blocking muscarinic receptors in the bladder, leading to **detrusor muscle relaxation** and increased bladder capacity. *Bumetanide* - **Bumetanide** is a **loop diuretic** used to treat **edema** and **hypertension** by increasing urine output. - It would worsen urinary incontinence rather than treat it by increasing the frequency and volume of urination. *Neostigmine* - **Neostigmine** is an **acetylcholinesterase inhibitor** used to treat conditions like **myasthenia gravis** or to reverse the effects of neuromuscular blockers. - It increases acetylcholine levels, which would **contract the detrusor muscle** and worsen urinary urgency and incontinence. *Metoprolol* - **Metoprolol** is a **beta-blocker** primarily used to treat **hypertension**, **angina**, and **heart failure**. - It has no direct primary role in treating urinary urgency and incontinence and could potentially exacerbate symptoms in some cases (e.g., in patients with obstructive voiding symptoms).

Q: Which one of the following increases the potassium level in the body –

Suxamethonium. ***Suxamethonium*** - **Suxamethonium** (succinylcholine) is a depolarizing neuromuscular blocker that causes a transient, dose-dependent release of potassium from muscle cells, leading to a rise in serum potassium levels. - This effect is due to its action on **nicotinic acetylcholine receptors**, which causes prolonged depolarization and opening of ion channels, allowing potassium to efflux from the cells. *Pancuronium* - **Pancuronium** is a non-depolarizing neuromuscular blocker that acts by competitively binding to nicotinic acetylcholine receptors without causing depolarization. - It does not cause a significant release of potassium from muscle cells and is not associated with hyperkalemia. *E–tubocurarine* - **Tubocurarine** is a non-depolarizing neuromuscular blocker that works by competing with acetylcholine for binding to nicotinic receptors at the neuromuscular junction. - It does not directly cause potassium release from cells and is not associated with an increase in serum potassium levels. *Gallamine* - **Gallamine** is a non-depolarizing neuromuscular blocker with a similar mechanism of action to pancuronium and tubocurarine. - It works by competitively antagonizing acetylcholine at the neuromuscular junction and does not cause clinically significant hyperkalemia.

Q: Laudanosine is a toxic metabolite of?

Atracurium. ***Atracurium*** - Atracurium undergoes **Hofmann elimination**, a non-enzymatic degradation process, which produces **laudanosine** as a metabolite. - **Laudanosine** can accumulate, particularly in patients with renal or hepatic dysfunction, and at high concentrations, it may cause **CNS excitation** and seizures. *Mivacurium* - Mivacurium is rapidly metabolized by **plasma pseudocholinesterase**, an enzyme also responsible for the breakdown of succinylcholine. - Its breakdown products do not include laudanosine, and it has a relatively **short duration of action** due to this rapid metabolism. *Vecuronium* - Vecuronium is primarily eliminated by the **liver** and, to a lesser extent, the kidneys, with metabolites having some neuromuscular blocking activity. - It does not undergo Hofmann elimination and therefore does not produce laudanosine as a metabolite. *Pancuronium* - Pancuronium is primarily eliminated by the **kidneys**, with a significant portion excreted unchanged. - It is a long-acting neuromuscular blocker and does not produce laudanosine as a metabolite.

Q: Mydriasis is caused by:

Atropine. ***Atropine*** - **Atropine** is an **anticholinergic drug** that blocks the action of **acetylcholine** at **muscarinic receptors** in the iris sphincter muscle. - This blockage leads to the relaxation of the **sphincter muscle**, causing **pupil dilation (mydriasis)** and loss of accommodation. *Horner syndrome* - **Horner syndrome** results from damage to the **sympathetic nervous pathway** to the eye. - It classically presents with a triad of **miosis** (constricted pupil), ptosis (drooping eyelid), and **anhydrosis** (decreased sweating) on the affected side. *Neurosyphilis* - **Neurosyphilis** can cause various neurological manifestations, including **Argyll Robertson pupils**. - **Argyll Robertson pupils** are characterized by **small, irregular pupils** that *accommodate but do not react to light* (miosis rather than mydriasis). *Organophosphorus poisoning* - **Organophosphorus compounds** inhibit **acetylcholinesterase**, leading to an excess of acetylcholine at cholinergic synapses. - This overstimulation causes **miosis** (pinpoint pupils), along with other cholinergic symptoms such as salivation, lacrimation, and bradycardia.

Q: All of the following are examples of mydriatics except –

Pirenzepine. ***Pirenzepine*** - **Pirenzepine** is an **M1-selective muscarinic antagonist** primarily used to treat peptic ulcers by reducing gastric acid secretion. - It does not significantly affect the **pupil** or cause **mydriasis** as its selectivity is for M1 receptors, which are not predominantly involved in pupillary dilation. *Tropicamide* - **Tropicamide** is a **muscarinic antagonist** that causes rapid and short-acting **mydriasis** and cycloplegia by blocking M3 receptors in the iris sphincter and ciliary body. - It is frequently used for ophthalmic examinations to dilate the pupil. *Atropine* - **Atropine** is a **non-selective muscarinic antagonist** that causes prolonged **mydriasis** and cycloplegia by blocking muscarinic receptors in the eye. - Its effects can last for several days, making it less suitable for routine ophthalmic examinations but useful in treating inflammatory conditions. *Homatropine* - **Homatropine** is a **muscarinic antagonist** with intermediate duration of action, causing **mydriasis** and cycloplegia. - It provides a longer-lasting effect than tropicamide but is shorter than atropine, making it useful in various ophthalmic procedures.

Q: Among atracurium and cisatracurium, which of the following does not require dose modification in patients with renal or hepatic failure?

Both atracurium and cisatracurium. ***Both atracurium and cisatracurium*** - Both **atracurium** and **cisatracurium** are metabolized primarily via **Hofmann elimination**, a non-enzymatic chemical degradation. - This mechanism is independent of renal or hepatic function, making them safe choices for patients with organ failure without requiring dose adjustment. *Cisatracurium* - While **cisatracurium** is known for its metabolism via **Hofmann elimination**, excluding atracurium from this category is incorrect. - Atracurium also undergoes significant Hofmann elimination, sharing this characteristic for organ-independent metabolism. *Atracurium* - While **atracurium** is metabolized via **Hofmann elimination**, excluding cisatracurium is incorrect, as cisatracurium also primarily utilizes this pathway. - Both agents are advantageous in patients with renal or hepatic impairment. *Neither atracurium nor cisatracurium* - This statement is incorrect because both drugs demonstrate metabolism independent of renal or hepatic function, which is a key advantage. - Their primary degradation pathway, **Hofmann elimination**, ensures that their elimination is not significantly affected by organ dysfunction.

Q: All of the following can aggravate Myasthenia gravis except :

Azathioprine. ***Azathioprine*** - **Azathioprine** is an **immunosuppressant** used to *treat* Myasthenia Gravis, meaning it *alleviates* symptoms rather than aggravating them. - It works by suppressing the immune system, thereby reducing the production of **acetylcholine receptor antibodies** that cause muscle weakness in Myasthenia Gravis. *Aminoglycoside* - **Aminoglycosides** can worsen Myasthenia Gravis by blocking **acetylcholine release** from nerve terminals and by stabilizing the **postsynaptic membrane**, further impairing neuromuscular transmission. - This effect is due to their structural similarities to **magnesium**, which can interfere with calcium-dependent acetylcholine release. *d–Tubocurarine* - **d-Tubocurarine** is a **non-depolarizing neuromuscular blocker** that acts by competing with **acetylcholine** for binding to its receptors on the muscle endplate. - Patients with Myasthenia Gravis have fewer functional acetylcholine receptors, making them highly susceptible to the effects of **neuromuscular blockers** and easily aggravated by them. *Tetracycline* - **Tetracyclines** can exacerbate Myasthenia Gravis by inhibiting **presynaptic acetylcholine release** and hindering the actions of **acetylcholine** on the postsynaptic membrane. - While less potent than aminoglycosides, they can still significantly worsen **muscle weakness** in affected individuals.

Question 1

Botulinum toxin is used in -

Accepted Answer

Focal dystonia

Answer

Myasthenia gravis

Answer

Cerebellar ataxia

Answer

Hypotonia

Question 2

The following drug antagonizes the visceral side effects of neostigmine used for reversal of vecuronium blockade:

Accepted Answer

Atropine

Answer

Pilocarpine

Answer

Pyridostigmine

Answer

Nicotine

Question 3

A 72 year old woman presents with complaints of persistent urinary urgency, and incontinence. Her past medical history is significant for type 2 diabetes, for which she is currently taking glyburide, 5 mg twice daily. Which of the following is the most appropriate treatment for this patient?

Accepted Answer

Oxybutynin

Answer

Bumetanide

Answer

Neostigmine

Answer

Metoprolol

Question 4

Which one of the following increases the potassium level in the body –

Accepted Answer

Suxamethonium

Answer

Pancuronium

Answer

E–tubocurarine

Answer

Gallamine

Question 5

Laudanosine is a toxic metabolite of?

Accepted Answer

Atracurium

Answer

Mivacurium

Answer

Vecuronium

Answer

Pancuronium

Question 6

Which of the following is true of botulinum toxin?

Accepted Answer

It inhibits the release of acetylcholine at the neuromuscular junction

Answer

It primarily affects the central nervous system

Answer

It is an endotoxin

Answer

It is a relatively weak neurotoxin

Question 7

Mydriasis is caused by:

Accepted Answer

Atropine

Answer

Horner syndrome

Answer

Neurosyphilis

Answer

Organophosphorus poisoning

Question 8

All of the following are examples of mydriatics except –

Accepted Answer

Pirenzepine

Answer

Tropicamide

Answer

Atropine

Answer

Homatropine

Question 9

Among atracurium and cisatracurium, which of the following does not require dose modification in patients with renal or hepatic failure?

Accepted Answer

Both atracurium and cisatracurium

Answer

Cisatracurium

Answer

Atracurium

Answer

Neither atracurium nor cisatracurium

Question 10

All of the following can aggravate Myasthenia gravis except :

Accepted Answer

Azathioprine

Answer

Aminoglycoside

Answer

d–Tubocurarine

Answer

Tetracycline

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?